Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Jubilant Pharmova Statistics

Total Valuation

NSE:JUBLPHARMA has a market cap or net worth of INR 173.85 billion. The enterprise value is 196.25 billion.

Market Cap	173.85B
Enterprise Value	196.25B

Important Dates

The last earnings date was Friday, October 31, 2025.

Earnings Date	Oct 31, 2025
Ex-Dividend Date	Jul 25, 2025

Share Statistics

Current Share Class	158.40M
Shares Outstanding	n/a
Shares Change (YoY)	-0.01%
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	7.67%
Owned by Institutions (%)	22.81%
Float	63.42M

Valuation Ratios

The trailing PE ratio is 36.39 and the forward PE ratio is 25.72.

PE Ratio	36.39
Forward PE	25.72
PS Ratio	2.28
PB Ratio	2.65
P/TBV Ratio	6.24
P/FCF Ratio	n/a
P/OCF Ratio	15.61
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.36, with an EV/FCF ratio of -197.23.

EV / Earnings	41.08
EV / Sales	2.58
EV / EBITDA	16.36
EV / EBIT	22.50
EV / FCF	-197.23

Financial Position

The company has a current ratio of 1.66, with a Debt / Equity ratio of 0.44.

Current Ratio	1.66
Quick Ratio	0.81
Debt / Equity	0.44
Debt / EBITDA	2.40
Debt / FCF	-28.97
Interest Coverage	4.64

Financial Efficiency

Return on equity (ROE) is 7.59% and return on invested capital (ROIC) is 5.91%.

Return on Equity (ROE)	7.59%
Return on Assets (ROA)	4.29%
Return on Invested Capital (ROIC)	5.91%
Return on Capital Employed (ROCE)	7.63%
Revenue Per Employee	13.73M
Profits Per Employee	861,186
Employee Count	5,547
Asset Turnover	0.60
Inventory Turnover	2.20

Taxes

In the past 12 months, NSE:JUBLPHARMA has paid 2.07 billion in taxes.

Income Tax	2.07B
Effective Tax Rate	30.36%

Stock Price Statistics

The stock price has decreased by -2.74% in the last 52 weeks. The beta is 0.68, so NSE:JUBLPHARMA's price volatility has been lower than the market average.

Beta (5Y)	0.68
52-Week Price Change	-2.74%
50-Day Moving Average	1,091.90
200-Day Moving Average	1,038.51
Relative Strength Index (RSI)	48.80
Average Volume (20 Days)	164,709

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NSE:JUBLPHARMA had revenue of INR 76.18 billion and earned 4.78 billion in profits. Earnings per share was 30.08.

Revenue	76.18B
Gross Profit	49.84B
Operating Income	8.73B
Pretax Income	6.81B
Net Income	4.78B
EBITDA	11.38B
EBIT	8.73B
Earnings Per Share (EPS)	30.08

Balance Sheet

The company has 6.23 billion in cash and 28.83 billion in debt, giving a net cash position of -22.60 billion.

Cash & Cash Equivalents	6.23B
Total Debt	28.83B
Net Cash	-22.60B
Net Cash Per Share	n/a
Equity (Book Value)	65.72B
Book Value Per Share	415.87
Working Capital	13.71B

Cash Flow

In the last 12 months, operating cash flow was 11.14 billion and capital expenditures -12.13 billion, giving a free cash flow of -995.00 million.

Operating Cash Flow	11.14B
Capital Expenditures	-12.13B
Free Cash Flow	-995.00M
FCF Per Share	n/a

Margins

Gross margin is 65.42%, with operating and profit margins of 11.46% and 6.27%.

Gross Margin	65.42%
Operating Margin	11.46%
Pretax Margin	8.94%
Profit Margin	6.27%
EBITDA Margin	14.94%
EBIT Margin	11.46%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 0.45%.

Dividend Per Share	5.00
Dividend Yield	0.45%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	16.68%
Buyback Yield	0.01%
Shareholder Yield	0.47%
Earnings Yield	2.75%
FCF Yield	-0.57%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on March 17, 2006. It was a forward split with a ratio of 5.

Last Split Date	Mar 17, 2006
Split Type	Forward
Split Ratio	5

Scores

Altman Z-Score	n/a
Piotroski F-Score	6